Stephanie Davis
Stock Analyst at Barclays
(0.62)
# 4,037
Out of 5,072 analysts
94
Total ratings
33.33%
Success rate
-109.47%
Average return
Main Sectors:
Stocks Rated by Stephanie Davis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DGX Quest Diagnostics | Maintains: Equal-Weight | $190 → $195 | $189.69 | +2.80% | 7 | Oct 22, 2025 | |
| WAY Waystar Holding | Maintains: Overweight | $50 → $45 | $37.04 | +21.49% | 6 | Apr 14, 2025 | |
| OPRX OptimizeRx | Maintains: Equal-Weight | $11 → $5 | $15.38 | -67.49% | 3 | Nov 14, 2024 | |
| DOCS Doximity | Maintains: Overweight | $52 → $75 | $50.97 | +47.15% | 5 | Nov 11, 2024 | |
| LFST LifeStance Health Group | Maintains: Underweight | $6 → $7 | $6.56 | +6.71% | 2 | Nov 11, 2024 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $10 → $6 | $2.83 | +112.01% | 7 | Nov 11, 2024 | |
| EVH Evolent Health | Maintains: Overweight | $39 → $19 | $4.20 | +352.38% | 1 | Nov 11, 2024 | |
| COR Cencora | Maintains: Overweight | $263 → $290 | $368.53 | -21.31% | 2 | Nov 7, 2024 | |
| CAH Cardinal Health | Maintains: Overweight | $117 → $133 | $213.14 | -37.60% | 2 | Nov 4, 2024 | |
| OMCL Omnicell | Maintains: Equal-Weight | $39 → $58 | $36.66 | +58.21% | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $3 | $3.41 | -12.02% | 7 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $213 → $249 | $268.27 | -7.18% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $29 | $20.53 | +41.26% | 11 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $7.45 | +356.38% | 9 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $59 → $34 | $26.70 | +27.34% | 3 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $242 → $233 | $240.67 | -3.19% | 9 | Dec 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $17 | $2.92 | +482.19% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $76 | $104.99 | -27.61% | 5 | Jun 7, 2022 |
Quest Diagnostics
Oct 22, 2025
Maintains: Equal-Weight
Price Target: $190 → $195
Current: $189.69
Upside: +2.80%
Waystar Holding
Apr 14, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $37.04
Upside: +21.49%
OptimizeRx
Nov 14, 2024
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $15.38
Upside: -67.49%
Doximity
Nov 11, 2024
Maintains: Overweight
Price Target: $52 → $75
Current: $50.97
Upside: +47.15%
LifeStance Health Group
Nov 11, 2024
Maintains: Underweight
Price Target: $6 → $7
Current: $6.56
Upside: +6.71%
GoodRx Holdings
Nov 11, 2024
Maintains: Overweight
Price Target: $10 → $6
Current: $2.83
Upside: +112.01%
Evolent Health
Nov 11, 2024
Maintains: Overweight
Price Target: $39 → $19
Current: $4.20
Upside: +352.38%
Cencora
Nov 7, 2024
Maintains: Overweight
Price Target: $263 → $290
Current: $368.53
Upside: -21.31%
Cardinal Health
Nov 4, 2024
Maintains: Overweight
Price Target: $117 → $133
Current: $213.14
Upside: -37.60%
Omnicell
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $39 → $58
Current: $36.66
Upside: +58.21%
Oct 29, 2024
Maintains: Equal-Weight
Price Target: $2 → $3
Current: $3.41
Upside: -12.02%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $213 → $249
Current: $268.27
Upside: -7.18%
Jan 3, 2024
Initiates: Overweight
Price Target: $29
Current: $20.53
Upside: +41.26%
Feb 23, 2023
Upgrades: Outperform
Price Target: $34
Current: $7.45
Upside: +356.38%
Jan 5, 2023
Downgrades: Market Perform
Price Target: $59 → $34
Current: $26.70
Upside: +27.34%
Dec 2, 2022
Maintains: Outperform
Price Target: $242 → $233
Current: $240.67
Upside: -3.19%
Nov 9, 2022
Maintains: Outperform
Price Target: $20 → $17
Current: $2.92
Upside: +482.19%
Jun 7, 2022
Maintains: Outperform
Price Target: $67 → $76
Current: $104.99
Upside: -27.61%